Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun 21.
doi: 10.1007/s10741-025-10539-6. Online ahead of print.

Skeletal muscle atrophy in pulmonary arterial hypertension: potential mechanisms and effects of physical exercise

Affiliations
Review

Skeletal muscle atrophy in pulmonary arterial hypertension: potential mechanisms and effects of physical exercise

Sebastião Felipe Ferreira Costa et al. Heart Fail Rev. .

Abstract

Pulmonary arterial hypertension (PAH) is a rare and progressive disease characterized by pathological remodeling of the pulmonary arteries, resulting in increased pulmonary vascular resistance and right ventricular overload. This condition triggers common symptoms such as dyspnea and exercise intolerance, compromising thus the quality of life of individuals affected by this pathology. Skeletal muscle atrophy is one of the main determinants of these symptoms, which is mediated by an imbalance between protein synthesis and degradation, triggered by adverse systemic adaptations promoted by PAH, such as decreased blood perfusion and increased inflammation. This review addresses the main cellular and molecular mechanisms that potentially trigger or inhibit protein degradation pathways, and how they interact in the context of PAH. Furthermore, we focus on physical exercise as a non-pharmacological approach capable of modulating muscle atrophy induced by PAH.

Keywords: Exercise intolerance; Inflammation; PAH; Pathological remodeling; Protein degradation.

PubMed Disclaimer

Conflict of interest statement

Declarations. Disclosures: None. Competing interests: The authors declare no competing interests.

Similar articles

References

    1. Cullivan S, Higgins M, Gaine S (2022) Diagnosis and management of pulmonary arterial hypertension. Breathe 18:220168. https://doi.org/10.1183/20734735.0168-2022 - DOI - PubMed - PMC
    1. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M et al (2022) ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European society of cardiology (ESC) and the European respiratory society (ERS). Endorsed by the international society for heart and lung transplantation (ISHLT) and the European reference network on rare respiratory diseases (ERN-LUNG). Eur Heart J 43:3618–3731. https://doi.org/10.1093/eurheartj/ehac237 - DOI - PubMed
    1. Thenappan T, Ormiston ML, Ryan JJ, Archer SL (2018) Pulmonary arterial hypertension: pathogenesis and clinical management. BMJ j5492. https://doi.org/10.1136/bmj.j5492
    1. Bogaard HJ, Abe K, Vonk Noordegraaf A, Voelkel NF (2009) The right ventricle under pressure. Chest 135:794–804. https://doi.org/10.1378/chest.08-0492 - DOI - PubMed
    1. Naeije R, Manes A (2014) The right ventricle in pulmonary arterial hypertension. Eur Respir Rev 23:476–487. https://doi.org/10.1183/09059180.00007414 - DOI - PubMed - PMC

LinkOut - more resources